Form 4: Apellis Director Alec Machiels Receives Equity Grants

Apellis Pharmaceuticals director Alec Machiels was granted 7,961 restricted stock units and 14,684 stock options on January 1, 2026.

Summary

• Alec Machiels, a Director of Apellis Pharmaceuticals, Inc., was granted 7,961 restricted stock units (RSUs) on January 1, 2026.
• These RSUs will fully vest on January 1, 2027, or upon later termination of his service as a director at his election, subject to his continued service.
• Machiels also received a grant of 14,684 stock options on January 1, 2026, with an exercise price of $25.12.
• The stock options vest quarterly on the last day of each quarter from the grant date, subject to his continued service as a director, and expire on December 31, 2033.
• Following these transactions, Machiels directly beneficially owns 384,989 shares of common stock.
• Indirect beneficial ownership includes 250,000 shares held by Bauhaus 1 LLC (where Machiels is managing member and trustee of the underlying trust), 11,950 shares owned by his spouse, and 150,000 shares held by his spouse's trust (where Machiels is the trustee).

Sentiment

Score: 7

Explanation: The filing reports routine equity compensation for a director, which is a positive for aligning management incentives with shareholder interests. There are no negative disclosures.

Positives

• The grants of 7,961 restricted stock units and 14,684 stock options align the director's interests with long-term shareholder value.
• The vesting schedules for both RSUs and stock options incentivize continued service and performance from a key director.

Future Outlook

The grants include vesting schedules that extend into the future, with restricted stock units vesting fully on January 1, 2027, and stock options vesting quarterly from the grant date until their expiration on December 31, 2033. These are tied to the director's continued service.

Industry Context

NA

Related Party Transactions

• Indirect beneficial ownership includes shares held by Bauhaus 1 LLC, where the reporting person is the managing member and trustee of the underlying trust.
• Indirect beneficial ownership includes shares owned by the reporting person's spouse.
• Indirect beneficial ownership includes shares held by the reporting person's spouse's trust, where the reporting person is the trustee.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with the company's long-term performance, potentially benefiting shareholders through motivated leadership.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The 7,961 restricted stock units are expected to fully vest on January 1, 2027, subject to continued service.
• The 14,684 stock options will vest quarterly from January 1, 2026, subject to continued service.

Key Dates

Keywords

Apellis Pharmaceuticals, APLS, Alec Machiels, Director, Restricted Stock Units, Stock Options, Equity Grant, Insider Transaction, Form 4, Beneficial Ownership